vs
Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
cbdMD, Inc. is the larger business by last-quarter revenue ($5.0M vs $4.8M, roughly 1.0× MAXCYTE, INC.). cbdMD, Inc. runs the higher net margin — -5.6% vs -200.5%, a 194.8% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -20.9%). cbdMD, Inc. produced more free cash flow last quarter ($-977.3K vs $-2.9M). Over the past eight quarters, cbdMD, Inc.'s revenue compounded faster (7.1% CAGR vs -7.4%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
MXCT vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $5.0M |
| Net Profit | $-9.6M | $-283.1K |
| Gross Margin | — | 59.8% |
| Operating Margin | -234.5% | -5.7% |
| Net Margin | -200.5% | -5.6% |
| Revenue YoY | -20.9% | -1.9% |
| Net Profit YoY | 9.4% | -1975.7% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $5.0M | ||
| Q3 25 | $4.6M | $4.7M | ||
| Q2 25 | $5.8M | $4.6M | ||
| Q1 25 | $5.7M | $4.7M | ||
| Q4 24 | $6.1M | $5.1M | ||
| Q3 24 | $5.6M | $4.6M | ||
| Q2 24 | $5.0M | $5.2M | ||
| Q1 24 | $5.6M | $4.4M |
| Q4 25 | $-9.6M | $-283.1K | ||
| Q3 25 | $-12.4M | $-680.0K | ||
| Q2 25 | $-12.4M | $-895.3K | ||
| Q1 25 | $-10.3M | $-480.8K | ||
| Q4 24 | $-10.6M | $15.1K | ||
| Q3 24 | $-11.6M | $-152.8K | ||
| Q2 24 | $-9.4M | $459.7K | ||
| Q1 24 | $-9.5M | $-3.0M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 62.3% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 53.9% | ||
| Q2 24 | — | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | -234.5% | -5.7% | ||
| Q3 25 | -307.4% | -14.5% | ||
| Q2 25 | -244.3% | -19.6% | ||
| Q1 25 | -214.1% | -10.2% | ||
| Q4 24 | -213.1% | -1.7% | ||
| Q3 24 | -250.4% | -6.9% | ||
| Q2 24 | -241.0% | -7.4% | ||
| Q1 24 | -219.8% | -35.4% |
| Q4 25 | -200.5% | -5.6% | ||
| Q3 25 | -269.7% | -14.4% | ||
| Q2 25 | -212.2% | -19.4% | ||
| Q1 25 | -178.7% | -10.1% | ||
| Q4 24 | -175.0% | 0.3% | ||
| Q3 24 | -205.9% | -3.4% | ||
| Q2 24 | -188.8% | 8.9% | ||
| Q1 24 | -170.6% | -68.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.12 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.11 | — | ||
| Q2 24 | $-0.09 | $-0.15 | ||
| Q1 24 | — | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.5M | $9.0M |
| Total Assets | $202.5M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.0M | $3.4M | ||
| Q3 25 | $105.7M | $2.3M | ||
| Q2 25 | $126.6M | $1.1M | ||
| Q1 25 | $138.3M | $1.8M | ||
| Q4 24 | $154.5M | $2.0M | ||
| Q3 24 | $153.8M | $2.5M | ||
| Q2 24 | $157.3M | $2.4M | ||
| Q1 24 | $157.5M | $2.1M |
| Q4 25 | $171.5M | $9.0M | ||
| Q3 25 | $180.3M | $7.2M | ||
| Q2 25 | $190.7M | $6.1M | ||
| Q1 25 | $199.4M | $665.8K | ||
| Q4 24 | $206.3M | $1.8M | ||
| Q3 24 | $213.3M | $2.0M | ||
| Q2 24 | $221.3M | $3.0M | ||
| Q1 24 | $226.4M | $3.1M |
| Q4 25 | $202.5M | $11.8M | ||
| Q3 25 | $213.5M | $10.4M | ||
| Q2 25 | $219.8M | $9.9M | ||
| Q1 25 | $230.0M | $10.9M | ||
| Q4 24 | $239.5M | $11.5M | ||
| Q3 24 | $248.6M | $10.6M | ||
| Q2 24 | $251.5M | $13.8M | ||
| Q1 24 | $257.9M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | $-812.5K |
| Free Cash FlowOCF − Capex | $-2.9M | $-977.3K |
| FCF MarginFCF / Revenue | -61.0% | -19.5% |
| Capex IntensityCapex / Revenue | 4.8% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-36.2M | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.7M | $-812.5K | ||
| Q3 25 | $-7.5M | $-240.7K | ||
| Q2 25 | $-9.9M | $-704.2K | ||
| Q1 25 | $-14.4M | $-189.5K | ||
| Q4 24 | $-7.8M | $-317.9K | ||
| Q3 24 | $-4.4M | $167.4K | ||
| Q2 24 | $-4.8M | $289.8K | ||
| Q1 24 | $-10.6M | $-704.1K |
| Q4 25 | $-2.9M | $-977.3K | ||
| Q3 25 | $-7.8M | $-243.6K | ||
| Q2 25 | $-10.4M | $-705.7K | ||
| Q1 25 | $-15.1M | $-205.0K | ||
| Q4 24 | $-8.0M | $-482.3K | ||
| Q3 24 | $-4.8M | $157.4K | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-11.4M | $-708.7K |
| Q4 25 | -61.0% | -19.5% | ||
| Q3 25 | -168.5% | -5.2% | ||
| Q2 25 | -179.2% | -15.3% | ||
| Q1 25 | -262.3% | -4.3% | ||
| Q4 24 | -131.6% | -9.4% | ||
| Q3 24 | -85.5% | 3.5% | ||
| Q2 24 | -103.3% | — | ||
| Q1 24 | -203.6% | -16.2% |
| Q4 25 | 4.8% | 3.3% | ||
| Q3 25 | 6.5% | 0.1% | ||
| Q2 25 | 10.0% | 0.0% | ||
| Q1 25 | 11.4% | 0.3% | ||
| Q4 24 | 2.4% | 3.2% | ||
| Q3 24 | 7.2% | 0.2% | ||
| Q2 24 | 5.9% | 0.0% | ||
| Q1 24 | 14.4% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
